Please use this identifier to cite or link to this item: http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/5302
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSelcuk, Leyla Baykal-
dc.contributor.authorAksan, Burak-
dc.contributor.authorKulakli, Sevgi-
dc.contributor.authorOguz, Isil Deniz-
dc.contributor.authorGundogdu, Mustafa-
dc.contributor.authorDere, Gokturk-
dc.contributor.authorOnder, Sevda-
dc.contributor.authorEtgu, Fatma-
dc.contributor.authorArica, Deniz Aksu-
dc.contributor.authorOguzer, Seyda Ece-
dc.contributor.authorAydemir, Burcu-
dc.contributor.authorArica, Ibrahim Etem-
dc.contributor.authorSaral, Yunus-
dc.contributor.authorYayli, Savas-
dc.date.accessioned2024-03-26T07:24:32Z-
dc.date.available2024-03-26T07:24:32Z-
dc.date.issued2022-
dc.identifier.citationSelcuk, LB., Aksan, B., Kulakli, S., Oguz, ID., Gündogdu, M., Dere, G., Onder, S., Etgu, F., Arica, DA., Oguzer, SE., Aydemir, B., Arica, IE., Saral, Y., Yayli, S. (2022). Incidence and Prognosis of COVID-19 in Patients with Psoriasis: A Multicenter Prospective Study from the Eastern Black Sea Region of Turkey. Acta Dermatovenerol. Croat., 30(4), 209-215en_US
dc.identifier.issn1330-027X-
dc.identifier.issn1847-6538-
dc.identifier.urihttps://www.webofscience.com/wos/woscc/full-record/WOS:000973473700018-
dc.identifier.urihttp://earsiv.odu.edu.tr:8080/xmlui/handle/11489/5302-
dc.descriptionWoS Categories: Dermatologyen_US
dc.descriptionWeb of Science Index: Science Citation Index Expanded (SCI-EXPANDED)en_US
dc.descriptionResearch Areas: Dermatologyen_US
dc.description.abstractCOVID-19 infection can have a poor prognosis, especial-ly in patients with chronic diseases and those receiving immunosup-pressive or immunomodulating therapies.This study aimed to investigate the severity of COVID-19 infection in patients with psoriasis and compare the infection severity for sys-temic treatments and comorbidities.We conducted a study in the dermatology clinics of five different centers in the Eastern Black Sea region of Turkey. Four hundred and eighty-eight patients were included, and 22.5% were confirmed as having COVID-19 infection.In our study, the frequency of hospitalization rates due to COVID-19 infection were similar (15.4%, 25.9% respectively) in patients receiv-ing biological treatment and receiving non-biological systemic treat-ment (P=0.344). Hospitalization rates were higher in patients with hypertension, androgenetic alopecia, and acitretin use (P=0.043, P=0.028, P=0.040).In conclusion, current biologic treatments and non-biologic system-ic treatments in patients with psoriasis did not appear to increase the risk of the severe form of COVID-19, except for acitretin.en_US
dc.language.isoengen_US
dc.publisherCROATION DERMATOVENEROLOGICAL SOC-ZAGREBen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19, psoriasis, comorbidity, biologic, non-bio-logic systemic drugsen_US
dc.titleIncidence and Prognosis of COVID-19 in Patients with Psoriasis: A Multicenter Prospective Study from the Eastern Black Sea Region of Turkeyen_US
dc.typearticleen_US
dc.relation.journalACTA DERMATOVENEROLOGICA CROATICAen_US
dc.contributor.departmentOrdu Üniversitesien_US
dc.contributor.authorID0000-0003-3755-4325en_US
dc.contributor.authorID0000-0003-2733-2534en_US
dc.contributor.authorID0000-0001-7886-1060en_US
dc.identifier.volume30en_US
dc.identifier.issue4en_US
dc.identifier.startpage209en_US
dc.identifier.endpage215en_US
Appears in Collections:Dahili Tıp Bilimleri

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.